Current Management of Patients With Diverticulosis and Diverticular Disease: A Survey From the 2nd International Symposium on Diverticular Disease

J Clin Gastroenterol. 2016 Oct:50 Suppl 1:S97-S100. doi: 10.1097/MCG.0000000000000645.

Abstract

Background: Management of diverticular disease (DD) remains a point of debate.

Goals: To investigate the current opinion of participants of the 2nd International Symposium on Diverticular Disease, on real-life management of patients with DD of the colon.

Study: Twelve questions were aimed at the diagnosis, treatment, and management options for diverticulosis and symptomatic DD.

Results: In total, 115 surveys from 8 European Countries were filled out. High fiber diet was widely prescribed in diverticulosis (59.1%). Probiotics (25%) were the most frequent prescribed drug, whereas 29.8% of participants did not prescribe any treatment in diverticulosis. Colonoscopy was frequently prescribed in symptomatic patients (69.3%), whereas 72.9% of participants did not prescribe any instrumental tool in their follow-up. Rifaximin, probiotics, and mesalazine were the most frequent prescribed drugs both in symptomatic patients (28.1, 14.9%, and 11.4%, respectively) and to prevent recurrence of the disease (42.5%, 12.4%, and 28.2%, respectively). With respect to laboratory exams, 57.9% of participants prescribed them during follow-up. The majority of participants (64.9%) managed suspected acute diverticulitis at home. Rifaximin, probiotics, and mesalazine were the most frequent prescribed drugs to prevent recurrence of the disease (32.2%, 13.2%, and 11.4%, respectively), whereas 25.4% of participants did not prescribe any drugs. Finally, no differences were found among gastroenterologists, surgeons, and general practitioners in managing this disease.

Conclusions: This surveys shows that current management of DD is similar between different medical specialities, generally in line with current literature.

MeSH terms

  • Anti-Infective Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colonoscopy / statistics & numerical data
  • Congresses as Topic
  • Disease Management*
  • Diverticular Diseases / therapy*
  • Diverticulosis, Colonic / therapy*
  • Europe
  • Gastroenterologists / statistics & numerical data
  • General Practitioners / statistics & numerical data
  • Humans
  • Mesalamine / therapeutic use
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Probiotics / therapeutic use
  • Rifamycins / therapeutic use
  • Rifaximin
  • Surgeons / statistics & numerical data
  • Surveys and Questionnaires

Substances

  • Anti-Infective Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Rifamycins
  • Mesalamine
  • Rifaximin